Drug intelligence / Profile preview

losartan + isosorbide mononitrate

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

This drug is a combination of two active pharmaceutical ingredients: losartan, an angiotensin II receptor blocker (ARB), and isosorbide mononitrate (ISMN), an organic nitrate. Losartan works by selectively blocking the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced blood pressure, and decreased aldosterone secretion. Isosorbide mononitrate acts as a nitric oxide donor; it relaxes vascular smooth muscle predominantly in veins but also in arteries, reducing cardiac preload and afterload. The combination may be used experimentally or off-label for additive antihypertensive effects or management of certain cardiovascular conditions such as hypertension with coexisting angina pectoris. There are no widely marketed fixed-dose products containing both agents together; use would typically involve co-prescription of individual drugs[1][3][4].

Other names
losartan + ISMNlosartan and isosorbide mononitrate
02

Targets

GUCY1B1 (Guanylate cyclase soluble subunit beta-1)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on losartan + isosorbide mononitrate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on losartan + isosorbide mononitrate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call